Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Bataller A, et al. Am J Hematol. 2023 Nov;98(11):1780-1790. doi: 10.1002/ajh.27070. Epub 2023 Sep 4. Am J Hematol. 2023. PMID: 37665752
The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients.
Mozas P, Sorigué M, Rivas-Delgado A, Rivero A, Correa JG, Castillo C, Nadeu F, Bataller A, Giné E, Baumann T, Delgado J, Villamor N, Campo E, Magnano L, Sancho JM, López-Guillermo A. Mozas P, et al. Among authors: bataller a. Eur J Haematol. 2021 Mar;106(3):428-432. doi: 10.1111/ejh.13556. Epub 2020 Dec 14. Eur J Haematol. 2021. PMID: 33247499 No abstract available.
Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma.
Mozas P, Rivero A, Rivas-Delgado A, Fabregat A, Piñeyroa JA, Correa JG, Nadeu F, Oliver A, Bataller A, Giné E, Delgado J, Villamor N, Cibeira MT, Fernández de Larrea C, Rosiñol L, Campo E, Aróstegui JI, Bladé J, Magnano L, López-Guillermo A. Mozas P, et al. Among authors: bataller a. Br J Haematol. 2021 Apr;193(2):299-306. doi: 10.1111/bjh.17138. Epub 2020 Nov 16. Br J Haematol. 2021. PMID: 33200406 Free article.
The role of TGFβ in hematopoiesis and myeloid disorders.
Bataller A, Montalban-Bravo G, Soltysiak KA, Garcia-Manero G. Bataller A, et al. Leukemia. 2019 May;33(5):1076-1089. doi: 10.1038/s41375-019-0420-1. Epub 2019 Feb 28. Leukemia. 2019. PMID: 30816330 Review.
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.
Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Almanza-Huante E, et al. Among authors: bataller a. Br J Haematol. 2023 May;201(3):e25-e29. doi: 10.1111/bjh.18766. Epub 2023 Mar 23. Br J Haematol. 2023. PMID: 36951293 No abstract available.
Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations.
Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Urrutia S, et al. Among authors: bataller a. Leukemia. 2023 Jun;37(6):1397-1400. doi: 10.1038/s41375-023-01899-9. Epub 2023 Apr 25. Leukemia. 2023. PMID: 37185307 No abstract available.
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Bazinet A, et al. Among authors: bataller a. Am J Hematol. 2023 Sep;98(9):1383-1393. doi: 10.1002/ajh.26997. Epub 2023 Jun 19. Am J Hematol. 2023. PMID: 37334870 Review.
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Urrutia S, et al. Among authors: bataller a. Am J Hematol. 2023 Oct;98(10):E281-E284. doi: 10.1002/ajh.27043. Epub 2023 Jul 29. Am J Hematol. 2023. PMID: 37515433
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Kadia TM, et al. Among authors: bataller a. Am J Hematol. 2023 Nov;98(11):1711-1720. doi: 10.1002/ajh.27054. Epub 2023 Aug 27. Am J Hematol. 2023. PMID: 37635400 Clinical Trial.
72 results